This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Raising Cash? American Home Cutting Immunex Stake

American Home Products (AHP - Get Report) said Wednesday it plans to reduce its majority stake in Immunex (IMNX), a top biotech company based in Seattle, in a move that could raise up to $2.7 billion.

But American Home denied that the move, which could cut its stake to 43% from 55%, was aimed at raising money to pay for rising costs to settle diet-drug litigation , a cost that the company acknowledged could balloon far beyond its original estimates. That cost has become an albatross for American Home shareholders, and, until the matter is resolved, the company isn't likely to be able to acquire other drug firms or to be acquired, observers say.

American Home said last month it may have to boost its reserves, currently about $3.3 billion, by "less than $5 billion" to pay for litigation from two diet drugs that were withdrawn in 1997. Analysts speculated the company could need as much as $3 billion more.


Lowell Weiner, a company spokesman, says the company is flush with cash. He says American Home will use the money from the Immunex stake sale to boost research and development and to fund other corporate purposes. The company recently got $1.8 billion as a merger breakup fee from its broken deal with Warner-Lambert, and an added $3.8 billion from the sale of its agrochemicals division.

"We don't need this cash to handle litigation," Weiner says. "We're confident the cost is manageable from existing resources." He says the company simply wanted to "monetize" stock gains from Immunex.

American Home said it plans to sell up to 50 million Immunex shares in a secondary offering, "market conditions permitting." Separately, Immunex said it filed to sell up to 20 million new Immunex shares.

But Perhaps Less Than a Full House

American Home inherited its stake in Immunex in 1994 when it bought American Cyanamid, an agrochemical and drug company. That purchase turned out to be hugely successful for American Home, allowing it to benefit from Immunex's rapid stock gains and giving it access to Enbrel, a fast-growing arthritis drug that both companies sell.

After the stock sale, American Home will continue to market Enbrel, the company said.

The move comes at a time when other drug companies are boosting their stakes in biotech companies, looking to bolster their product offerings as in-house research-and-development operations become less productive. Genentech (DNA), for instance, is 59% held by Roche, while Chiron (CHIR) is about 44% held by Novartis (NVS).

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AHP $14.12 -0.14%
AAPL $118.88 0.96%
FB $105.75 -1.10%
GOOG $748.29 -1.00%
TSLA $218.25 0.23%


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs